Metoclopramide-Induced Acute Dystonic Reactions May Be Associated With the CYP2D6 Poor Metabolizer Status and Pregnancy-Related Hormonal Changes

被引:12
|
作者
Chua, Eng Wee [1 ]
Harger, Simon P. [2 ]
Kennedy, Martin A. [3 ,4 ]
机构
[1] Univ Kebangsaan Malaysia, Fac Pharm, Kuala Lumpur, Malaysia
[2] Hawkes Bay Dist Hlth Board, Hastings, New Zealand
[3] Univ Otago, Carney Ctr Pharmacogen, Christchurch, New Zealand
[4] Univ Otago, Dept Pathol & Biomed Sci, Christchurch, New Zealand
来源
FRONTIERS IN PHARMACOLOGY | 2019年 / 10卷
关键词
metoclopramide; acute dystonia; CYP2D6; poor metabolizer; pregnancy; estrogen; dopamine; EXTRAPYRAMIDAL REACTIONS; PHARMACOKINETICS; POPULATION; INHIBITOR;
D O I
10.3389/fphar.2019.00931
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
We report two cases of metoclopramide-induced acute dystonia in pregnant women and consider the role of genetic variation in the pathogenesis of the adverse effect. By whole-gene sequencing, we found that both women were CYP2D6 poor metabolizers. We theorize that CYP2D6 governs the risk of metoclopramide-related acute dystonia through its role in the synthesis of serotonin, which inhibits the dopamine tone. The effect of CYP2D6 poor metabolism is exaggerated by rises in the estrogen levels during pregnancy, as the hormone augments dopamine sensitivity. Together, the two factors may create a hyper-dopaminergic state that is easily upset by metoclopramide, resulting in acute dystonia.
引用
收藏
页数:5
相关论文
共 37 条
  • [1] Metoclopramide-induced acute dystonic reaction caused by CYP2D6*4/*4 and CYP2D6*10/*10 genotypes
    Sarac, I.
    Sarac, H.
    Borovecki, F.
    Bozina, N.
    Ivek, I.
    Krakan, L. Bagaric
    Kresic, Z.
    MOVEMENT DISORDERS, 2023, 38 : S371 - S371
  • [2] Case report: metoclopramide induced acute dystonic reaction in adolescent CYP2D6 poor metabolizers
    Fink, Franz-Martin
    Bognar, Marta
    Hengl, Petra
    Paulmichl, Markus
    Nofziger, Charity
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [3] The CYP2D6 poor metabolizer phenotype may be associated with risperidone adverse drug reactions and discontinuation
    de Leon, J
    Susce, MT
    Pan, RM
    Fairchild, M
    Koch, WH
    Wedlund, PJ
    JOURNAL OF CLINICAL PSYCHIATRY, 2005, 66 (01) : 15 - 27
  • [4] CYP2D6 poor metabolizer status might be associated with better response to risperidone treatment
    Almoguera, Berta
    Riveiro-Alvarez, Rosa
    Lopez-Castroman, Jorge
    Dorado, Pedro
    Vaquero-Lorenzo, Concepcion
    Fernandez-Piqueras, Jose
    LLerena, Adrian
    Abad-Santos, Francisco
    Baca-Garcia, Enrique
    Dal-Re, Rafael
    Ayuso, Carmen
    PHARMACOGENETICS AND GENOMICS, 2013, 23 (11): : 627 - 630
  • [5] CYP2D6*36 gene arrangements within the CYP2D6 locus:: Association of CYP2D6*36 with poor metabolizer status
    Gaedigk, A
    Bradford, LD
    Alander, SW
    Leeder, JS
    DRUG METABOLISM AND DISPOSITION, 2006, 34 (04) : 563 - 569
  • [6] ASSOCIATION OF CYP2D6 METABOLIZER STATUS WITH ANTIDEPRESSANT INDUCED MANIA
    Beaupre, Lindsay Melhuish
    Zai, Clement
    Tiwari, Arun
    Mundo, Emanuela
    Shaikh, Sajid
    Tampakeras, Maria
    Freeman, Natalie
    Kennedy, James L.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S865 - S865
  • [7] ROLE OF THE CYP2D6 POOR METABOLIZER STATUS ON THE FIBROSIS PROGRESSION AFTER LIVER TRANSPLANTATION
    Zimmermann, T.
    Hoppe-Lotichius, M.
    Koerner, A.
    Lautem, A.
    Galle, P. R.
    Schuchmann, M.
    Otto, G.
    TRANSPLANT INTERNATIONAL, 2010, 23 : 3 - 3
  • [8] Can CYP2D6 poor metabolizer (PM) status be ruled out by a single genotyping assay?
    Gaedigk, A
    Bradford, LD
    Leeder, JS
    DRUG METABOLISM REVIEWS, 2002, 34 : 152 - 152
  • [9] A rare insertion of T-226 in exon 1 of CYP2D6 causes a frameshift and is associated with the poor metabolizer phenotype: CYP2D6*15
    Sachse, C
    Brockmoller, J
    Bauer, S
    Reum, T
    Roots, I
    PHARMACOGENETICS, 1996, 6 (03): : 269 - 272
  • [10] A NOVEL CYP2D6 ALLELE WITH AN ABOLISHED SPLICE RECOGNITION SITE ASSOCIATED WITH THE POOR METABOLIZER PHENOTYPE
    MAREZ, D
    SABBAGH, N
    LEGRAND, M
    LOGUIDICE, JM
    BOONE, P
    BROLY, F
    PHARMACOGENETICS, 1995, 5 (05): : 305 - 311